You have free access to this content

Clinical Liver Disease

Cover image for Clinical Liver Disease

Edited By: Michael Lucey, MD

Online ISSN: 2046-2484

Associated Title(s): Hepatology, Liver Transplantation

Recently Published Issues

See all

  • Current Issue:August 2014

    Volume 4, Issue 2

    Special Issue: Liver-Lung Syndromes

  • July 2014

    Volume 4, Issue 1

    Special Issue: Drug-Induced Liver Injury (DILI)

  • June 2014

    Volume 3, Issue 6

    Special Issue: Vascular Disorders

  • May 2014

    Volume 3, Issue 5

    Special Issue: Heavy Metals and the Liver

  • April 2014

    Volume 3, Issue 4

    Special Issue: Autoimmune Liver Disease, Part 4

Liver-Lung Syndromes

Guest Edited by: Michael B. Fallon, M.D.

Hepatic Hydrothorax: Current Concepts
Karen L. Krok, M.D.
Hepatic hydrothorax is an uncommon complication of portal hypertension, but when it does occur, portends a poor outcome and presents challenging treatment problems for clinicians.
Read the full textListen to the article presentationAnswer questions and earn CME



Liver Transplantation for Hepatopulmonary Syndrome
Vivek N. Iyer M.D., M.P.H.
Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are often considered together as pulmonary vascular complications of end-stage liver disease(ESLD), however the clinical presentation, pathophysiology and management of HPS and POPH are quite distinct from each other - learn how to recognize the differences.
Read the full textListen to the article presentationAnswer questions and earn CME



Portopulmonary Hypertension: Diagnosis, Clinical Features, and Medical Therapy
Sonja D. Bartolome, M.D.
A cardiac MRI of a patient with POPH
Dr. Bartolome reviews the pathophysiology, epidemiology, prognosis, clinical features, diagnosis, and management of PH.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



HPS: Diagnosis, Clinical Features, and Medical Therapy
Valentin Fuhrmann Ph.D., Andreas Drolz M.D., Karoline Rutter M.D., and Thomas Horvatits M.D.
HPS is the most frequent complication of the pulmonary vascular bed in patients with liver cirrhosis, and is found in up to 30% of patients undergoing evaluation for LTX (liver transplantation). HPS is also reported in other forms of acute and chronic noncirrhotic liver diseases such as acute liver failure, hypoxic hepatitis, and chronic viral hepatitis, making early detection initiation of appropriate therapy key for patient outcomes.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

For a more comprehensive review of the liver-lung syndromes, read a recent review by Drs . Machiacao, Balakrishnan and Fallon:

Machicao VI, Balakrishnan, Fallon MB. Pulmonary complications in chronic liver disease. Hepatoloty. 59:4 1627–1637, April 2014

Series on New Treatments for Hepatitis C

Guest Edited by Donald M. Jensen, M.D., F.A.C.P.

HCV Testing and Linkage to Care:
Expanding Access

Nancy Reau, M.D.
The limitation to HCV therapy is not treatment efficacy; it's identification of patients and linking them to providers interested in delivering antiviral therapy. Where does the system break down? Dr. Nancy Reau investigates.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

Read Dr. Reau's recent editorial in Hepatology:

Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 59:4 1246–1249, April, 2014.

New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

For more information related to HCV genotypes, read:Goossens N, Negro F. Is genotype 3 of hepatitis C virus the new villian? Hepatology. 59:6, 2403–2412, June 2014.



New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Read the full textListen to the article presentationAnswer questions and earn CME



Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.
Read the full textListen to the article presentationAnswer questions and earn CME

Test your knowledge! Use the Hepatitis C Self Assessment to complete board-style practice questions.

More on Liver-Lung Syndromes

Coming soon in next month's issue:

Liver Transplantation for Portopulmonary Hypertension
James Runo, M.D.


iTunes logo

Access CLD on the go.
Listen to the author interviews and readings of the full articles by subscribing to the iTunes podcast.


Find CLD on Facebook

Follow CLD on Twitter

SEARCH

SEARCH BY CITATION